Genetics/Genomics News

The FDA has approved the use of Veopoz for treatment of adults and children aged 1 year and older with CHAPLE disease, also known as CD55-deficient protein-losing enteropathy.

Following SARS-CoV-2 infection, mitochondrial function remained impaired in the heart, liver and kidneys, despite observed recovery in the lungs, according to a human autopsy and animal tissue study.

This year’s American Society for Nutrition Scientific Sessions and Annual Meeting will take place in person in Boston from July 22 to 25.

Congenital heart defects are the most common type of birth defect, affecting nearly 1% of births per year in the United States, according to the CDC.

Self-reported and genotype-predicted mean alcohol intake are associated with a higher burden of carotid plaque among a cohort of Chinese men, but not carotid intima-media thickness, researchers reported.

Evinacumab-dgnb was estimated to increase life expectancy an additional 12 years among patients with homozygous familial hypercholesterolemia already on standard-of-care lipid-lowering therapies, researchers reported.

Rocket Pharmaceuticals announced that the FDA has granted fast track and orphan drug designations to its adeno-associated virus-based gene therapy for the treatment of plakophilin-2-related arrhythmogenic cardiomyopathy.

An Australian general practitioner-led screening and care program for heterozygous familial hypercholesterolemia was projected to be cost-effective with significant return on investment vs. standard care, researchers reported.

PCSK9 inhibition with alirocumab, on top of high-intensity statin therapy, resulted in significant coronary plaque regression among patients with familial hypercholesterolemia and no clinical atherosclerotic CVD, researchers reported.

Adults with a genetically predicted high BMI may have a lower risk for cardiovascular disease than those whose obesity is linked more to environmental factors, according to a study published in eClinicalMedicine.